Clarence Ahlem
Operationeel Directeur bij NeurMedix, Inc.
Vermogen: 16 939 $ op 31-05-2024
Profiel
Clarence Ahlem currently works at NeurMedix, Inc., as Chief Operating Officer.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
BIOVIE INC. CLASS A
0.06% | 16-02-2023 | 37 148 ( 0.06% ) | 16 939 $ | 31-05-2024 |
Actieve functies van Clarence Ahlem
| Bedrijven | Functie | Begin |
|---|---|---|
NeurMedix, Inc.
 NeurMedix, Inc. Pharmaceuticals: MajorHealth Technology NeurMedix, Inc. is a clinical-stage biopharmaceutical company that develops products for the treatment of neurological and neuro-degenerative disorders and certain cancers. NeurMedix is based in San Diego, CA, and was founded by Terren S. Peizer, who has been the CEO since incorporation. The private company's product candidates have completed several pre-clinical and clinical studies, indicating its broad anti-inflammatory effect without evidence of immunosuppression. NeurMedix has invested over $85 million in developing NE3107, and its focus is on diseases with significant unmet medical needs and commercial potential. The company plans to enter clinical trials for the treatment of Parkinson's disease and several oncological indications later this year. | Operationeel Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
NeurMedix, Inc.
NeurMedix, Inc. Pharmaceuticals: MajorHealth Technology NeurMedix, Inc. is a clinical-stage biopharmaceutical company that develops products for the treatment of neurological and neuro-degenerative disorders and certain cancers. NeurMedix is based in San Diego, CA, and was founded by Terren S. Peizer, who has been the CEO since incorporation. The private company's product candidates have completed several pre-clinical and clinical studies, indicating its broad anti-inflammatory effect without evidence of immunosuppression. NeurMedix has invested over $85 million in developing NE3107, and its focus is on diseases with significant unmet medical needs and commercial potential. The company plans to enter clinical trials for the treatment of Parkinson's disease and several oncological indications later this year. | Health Technology |
